Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -17.02% is 23% below its 5-year average of -13.88%, near the low end of its 5-year range (-28.99%–13.72%).
18.97% above its 12-month average of -21.01%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.44%.
RETURN ON ASSETS (ROA)
-17.02%
RETURN ON ASSETS (ROA) AVG TTM
-21.01%
RETURN ON ASSETS (ROA) AVG 3Y
-19.47%
RETURN ON ASSETS (ROA) AVG 5Y
-13.88%
RETURN ON ASSETS (ROA) AVG 10Y
-14.44%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+18.97%
CURRENT VS 3Y AVG
+12.59%
CURRENT VS 5Y AVG
-22.67%
CURRENT VS 10Y AVG
-17.87%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.94%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
-444.53%
vs the sector median at left
CRISPR Therapeutics AG
Market Cap
$5.33B
Return on Assets (ROA)
-17.02%
TTM Avg
-21.01%
3Y Avg
-19.47%
5Y Avg
-13.88%
Market Cap
$5.21B
Return on Assets (ROA)
15.41%
TTM Avg
17.55%
3Y Avg
14.67%
5Y Avg
15.71%
Market Cap
$5.10B
Return on Assets (ROA)
5.08%
TTM Avg
4.88%
3Y Avg
4.58%
5Y Avg
3.44%
Market Cap
$5.60B
Return on Assets (ROA)
-78.04%
TTM Avg
-72.67%
3Y Avg
-59.05%
5Y Avg
-50.29%
Market Cap
$6.45B
Return on Assets (ROA)
-3.91%
TTM Avg
11.88%
3Y Avg
0.12%
5Y Avg
-6.73%
Market Cap
$6.64B
Return on Assets (ROA)
17.41%
TTM Avg
17.14%
3Y Avg
16.98%
5Y Avg
18.36%
Market Cap
$2.74B
Return on Assets (ROA)
10.36%
TTM Avg
11.11%
3Y Avg
1.40%
5Y Avg
-7.68%
Market Cap
$8.03B
Return on Assets (ROA)
4.91%
TTM Avg
-3.24%
3Y Avg
-6.85%
5Y Avg
-10.42%
Market Cap
$2.52B
Return on Assets (ROA)
-6.16%
TTM Avg
-19.77%
3Y Avg
-17.54%
5Y Avg
-23.06%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | $5.33B | -17.02% | -21.01% | -19.47% | -13.88% |
| Doximity, Inc. (DOCS)vs › | $5.21B | 15.41% | 17.55% | 14.67% | 15.71% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 5.08% | 4.88% | 4.58% | 3.44% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.60B | -78.04% | -72.67% | -59.05% | -50.29% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.45B | -3.91% | 11.88% | 0.12% | -6.73% |
| Chemed Corporation (CHE)vs › | $6.64B | 17.41% | 17.14% | 16.98% | 18.36% |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 10.36% | 11.11% | 1.40% | -7.68% |
| Oscar Health, Inc. (OSCR)vs › | $8.03B | 4.91% | -3.24% | -6.85% | -10.42% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | -6.16% | -19.77% | -17.54% | -23.06% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.14B | -42.79% | -37.88% | -40.02% | -36.63% |
ROA
-17.0%
ROE
-25.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -25.67% |
| 2024-12-31 | -16.34% |
| 2023-12-31 | -6.89% |
| 2022-12-31 | -28.99% |
| 2021-12-31 | 13.72% |
| 2020-12-31 | -19.08% |
| 2019-12-31 | 6.27% |
| 2018-12-31 | -33.74% |
| 2017-12-31 | -25.19% |
| 2016-12-31 | -6.73% |
| 2015-12-31 | -16.20% |
| 2014-12-31 | -445.32% |
